GenScript Biotech

GenScript Biotech Corporation (Stock Code: 1548.HK) is a global biotechnology group, founded in New Jersey, United States in 2002, by Dr. Fangliang (Frank) Zhang,[6] Mrs. Ye (Sally) Wang,[7] and Dr. Luquan Wang,[8] and listed on the Hong Kong Stock Exchange in 2015. The rotating CEO of GenScript is currently Shao Weihui.[9] GenScript’s legal entities located in the US, mainland China, Hong Kong China, Japan, Singapore, the Netherlands, Ireland and other countries and regions. GenScript operates in more than 100 countries and regions around the world. For a long time, GenScript has provided high-quality, convenient and reliable services and products to more than 200,000 customers.[10] As of June 30, 2022, GenScript had more than 5500 employees globally.[11]

GenScript Biotech
TypePublic
SEHK: 1548
IndustryList of life sciences
FoundedNew Jersey, U.S.（2002 (2002)）
FounderFangliang Zhang,[1] Ye Wang,[2] Luquan Wang[3]
Headquarters860 Centennial Avenue, Piscataway, New Jersey, U.S.
ProductsBiopharmaceutical
ServicesGene therapy[4]
Number of employees
5573（2022）[5]
Websitegenscript.com

GenScript consists of four major groups:

History

GenScript was founded in 2002 in New Jersey, and in 2004 established a research and production center in Nanjing, China. In 2011, the company opened a new Nanjing research and production facility and established a subsidiary in Japan. In 2013, the company launched a subsidiary called Bestzyme, focused on industrial synthetic biology products, followed by Legend Biotech in 2014, focused on cell therapy.

In 2015, GenScript Biotech Corporation was listed on the Hong Kong Stock Exchange under stock code 1548. In 2017, the China Food and Drug Administration (CFDA) accepted an investigational new drug (IND) application by Legend Biotech, leading to the establishment of a collaboration on a B-cell maturation antigen (BCMA) program between Legend and Janssen Pharmaceuticals. In 2018, Legend's BCMA program received IND clearance in the United States and China. GenScript's Biologics CDMO segment was established shortly thereafter.

In 2019, GenScript launched its new Biologics GMP CDMO R&D center and established its European and Asia-Pacific division. Legend's BCMA program received Orphan drug designation (FDA) & PRIME designation (EMA), US phase 1b data at ASH 2019: ORR 100%.

In 2020, GenScript and Duke-NUS Medical School co-developed a cPass sVNT kit, first in the world SARS-CoV-2 serology test to detect neutralizing antibodies.[14][15][16] Legend Biotech was listed on NASDAQ under stock code LEGN.[17]

GenScript participated as a sponsor of the 2021 International Genetically Engineered Machine Synthetic Biology Competition (iGEM).[18]

Operations

GenScript owns a number of intellectual property rights and trade secrets, Including over 190 patents, over 820 pending patent applications.[19]

GenScript Life Science Group

GenScript Life Science Group is GenScript's original business unit. Based on its independent and leading gene synthesis technology, the GenScript Life Science business has grown to become the world's largest gene synthesis provider with a market share of approximately 30%. As of June 30, 2022, over 74,700 peer-reviewed journal articles[20] worldwide have cited GenScript Biotech's services and products.

GenScript ProBio – Bio-pharmaceutical CDMO

GenScript ProBio is the bio-pharmaceutical CDMO segment,[21] which has established companies in the United States, the Netherlands, South Korea, and China (Hong Kong, Shanghai, and Nanjing) and other regions.[22], As of September, 2022, GenScript ProBio assisted the clients in receiving 37 IND approvals.[23]

Legend Biotech – Cell Therapy

A a subsidiary of GenScript Biotech Corporation, Legend Biotech (NASDAQ: LEGN) is a global clinical-stage biopharmaceutical company engaged in the discovery and development of novel cell therapies for oncological and other indications. With a team of more than 650 employees located in the US, China and Europe, Legend Biotech has a differentiated technology development and manufacturing strategy and expertise, Legend Biotech is dedicated to developing and manufacturing cell therapies for patients in need.[24]

Legend Biotech has established a strategic collaboration with Janssen Biotech to develop and commercialize the lead product candidate, LCAR-B38M/JNJ-4528, an investigational BCMA-targeted CAR-T cell therapy for patients living with relapsed or refractory multiple myeloma. This candidate is currently being studied in registrational clinical trials.

Bestzyme – Industrial Synthesis Product

Nanjing Bestzyme Bioengineering Co., Ltd. (Bestzyme) is one of GenScript's subsidiaries[25]，conducts industrial synthetic biology product business，integrates the development of enzyme preparations and the R&D, production, and sales of enzyme catalysis technology for active product ingredients (API).[26]

References
  1. "Is Genscript Biotech Corporation's (HKG:1548) CEO Salary Justified?". finance.yahoo.com. Retrieved 27 March 2020.
  2. "Corporate Governance". www.genscript.com.
  3. "Corporate Governance". www.genscript.com.
  4. "GenScript and Genopis Enter Into Strategic Partnership Agreement for Manufacture Service of GMP Plasmids-PR Newswire APAC". en.prnasia.com. Retrieved 27 March 2020.
  5. Interim Report (PDF) (Report). 2022.
  6. "Corporate Governance". www.genscript.com.
  7. "Corporate Governance". www.genscript.com.
  8. "Corporate Governance". www.genscript.com.
  9. REDESIGNATION OF DIRECTOR AND APPOINTMENT OF ROTATING CHIEF EXECUTIVE OFFICER (PDF) (Report). 2022.
  10. "GenScript Expands Footprint in Singapore to Provide Premium Gene Synthesis Service". markets.ft.com. Retrieved 2023-02-28.
  11. Interim Report (PDF) (Report). 2022.
  12. Magazine, Milestone (2019-08-17). "Frank Fangliang Zhang, Ph.D. - Founder CEO GenScript". Milestone Magazine. Retrieved 2020-10-23.
  13. "Company Overview GenScript". www.genscript.com. Retrieved 2020-10-23.
  14. "Duke-NUS, GenScript and A*STAR launch first-in-the-world SARS-CoV-2 serology test to detect neutralising antibodies without need of containment facility or specimen". www.genscript.com. Retrieved 2020-10-23.
  15. Corporation, Genscript Biotech. "GenScript Announces Publication of Clinical Data On New Method for Detecting COVID-19 Neutralizing Antibodies In Nature Biotechnology". www.prnewswire.com. Retrieved 2020-10-23.
  16. "A New Test May Show Whether Your Immune System Can Neutralize The Coronavirus". www.genscript.com. Retrieved 2020-10-23.
  17. Wong, Deborah; Yeung, Jessie (2020-06-05). "Legend Biotech Corporation Announces Pricing of Initial Public Offering". Business Wire. Archived from the original on 2022-12-17. Retrieved 2022-12-17.
  18. "Sponsors". iGEM 2021. Archived from the original on 2022-12-17. Retrieved 2022-12-17.
  19. "GenScript Partners with Allozymes to Accelerate Protein Discovery and Target Identification". www.prnewswire.com. Retrieved 2022-12-07.
  20. Interim Report (PDF) (Report). 2022.
  21. "News & Activities". www.genscriptprobio.com. Retrieved 2020-10-23.
  22. "End-to-End CDMO Service - GenScript ProBio". www.genscriptprobio.com.
  23. "Expanding GenScript ProBio's CDMO Global Market". www.genengnews.com. Retrieved 2022-10-06.
  24. "Legend Biotech Corporation Announces Pricing of Initial Public Offering". www.biospace.com. Retrieved 2020-06-05.
  25. "Genscript Biotech : CHANGE OF CHIEF EXECUTIVE OFFICER AND REDESIGNATION OF DIRECTOR". marketscreener.com. Retrieved 2020-08-02.
  26. "GenScript Biotech Reports First Half 2021 Results". www.prnewswire.com. Retrieved 2021-08-24.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.